首页    期刊浏览 2024年11月24日 星期日
登录注册

文章基本信息

  • 标题:Tetrandrine Prevents Bone Loss in Sciatic-Neurectomized Mice and Inhibits Receptor Activator of Nuclear Factor κB Ligand-Induced Osteoclast Differentiation
  • 本地全文:下载
  • 作者:Tatsuo Takahashi ; Yusuke Tonami ; Mami Tachibana
  • 期刊名称:Biological and Pharmaceutical Bulletin
  • 印刷版ISSN:0918-6158
  • 电子版ISSN:1347-5215
  • 出版年度:2012
  • 卷号:35
  • 期号:10
  • 页码:1765-1774
  • DOI:10.1248/bpb.b12-00445
  • 出版社:The Pharmaceutical Society of Japan
  • 摘要:One of the mediators of osteoclast differentiation is receptor activator of nuclear factor κB ligand (RANKL), which is produced by osteoblasts. Binding of RANKL to its receptor, RANK, activates several signaling pathways, including those involving mitogen-activated protein kinases (MAPKs), nuclear factor κB (NF-κB), nuclear factor of activated T cells c1 (NFATc1) and Ca2+-calcineurin. In the present study, we found that tetrandrine, a bisbenzylisoquinoline alkaloid extracted from the root of Stephania tetrandra S. M OORE , significantly ameliorated the decrease of bone mass in sciatic-neurectomized osteoporosis model mice. It appears that tetrandrine acts directly on osteoclast precursors, since tetrandrine inhibited osteoclast differentiation not only in mouse bone marrow cells, but also in monocultures of murine macrophage RAW 264.7 cells without osteoblasts. Tetrandrine suppressed RANKL-induced amplification of NFATc1, a master regulator of osteoclast differentiation. However, it did not affect other signaling molecules such as MAPKs and NF-κB. These results suggest that tetrandrine is a candidate for the treatment of bone-destructive diseases, or at least a suitable lead compound for further development.
  • 关键词:tetrandrine;osteoporosis;osteoclast;receptor activator of nuclear factor κB ligand;nuclear factor of activated T cell c1
国家哲学社会科学文献中心版权所有